Course of Disease and Clinical Management of Patients with Poorly Differentiated Thyroid Carcinoma.
18F-FDG-PET/CT
PDTC
poorly differentiated thyroid cancer
radioiodine therapy
risk stratification
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
22 Oct 2021
22 Oct 2021
Historique:
received:
28
09
2021
revised:
18
10
2021
accepted:
19
10
2021
entrez:
13
11
2021
pubmed:
14
11
2021
medline:
14
11
2021
Statut:
epublish
Résumé
In patients with poorly differentiated thyroid carcinoma, the clinical course and prognostic value of response to initial radioiodine therapy is evaluated. In 47 patients, clinical and imaging features were analyzed. Patients were stratified in no (NED), biochemical (B-ED) and structural evidence of disease (S-ED) assessed at the first diagnostic control and its impact on survival was evaluated. Further, possible risk factors for a shorter disease-specific survival rate (DSS) were analyzed. In total, 17/47 patients consisted of NED, 10/47 were B-ED and 20/47 S-ED patients. At the last follow-up, 18/47 patients were NED, 2/47 patients B-ED and 27/47 patients S-ED. The median survival time was only reached for the S-ED group (median 3.9 years, 95%CI 2.8-5.1 years) and was not reached in the B-ED and NED groups. Metastases were diagnosed by a The response to initial surgery and radioiodine therapy in PDTC patients can achieve an excellent outcome and a further follow-up should be refined based on findings at the first diagnostic control. However, patients with an incomplete response and metastatic patients who become mostly radioiodine refractory show a significantly shorter survival, which makes accurate staging by
Sections du résumé
BACKGROUND
BACKGROUND
In patients with poorly differentiated thyroid carcinoma, the clinical course and prognostic value of response to initial radioiodine therapy is evaluated.
METHODS
METHODS
In 47 patients, clinical and imaging features were analyzed. Patients were stratified in no (NED), biochemical (B-ED) and structural evidence of disease (S-ED) assessed at the first diagnostic control and its impact on survival was evaluated. Further, possible risk factors for a shorter disease-specific survival rate (DSS) were analyzed.
RESULTS
RESULTS
In total, 17/47 patients consisted of NED, 10/47 were B-ED and 20/47 S-ED patients. At the last follow-up, 18/47 patients were NED, 2/47 patients B-ED and 27/47 patients S-ED. The median survival time was only reached for the S-ED group (median 3.9 years, 95%CI 2.8-5.1 years) and was not reached in the B-ED and NED groups. Metastases were diagnosed by a
CONCLUSION
CONCLUSIONS
The response to initial surgery and radioiodine therapy in PDTC patients can achieve an excellent outcome and a further follow-up should be refined based on findings at the first diagnostic control. However, patients with an incomplete response and metastatic patients who become mostly radioiodine refractory show a significantly shorter survival, which makes accurate staging by
Identifiants
pubmed: 34771473
pii: cancers13215309
doi: 10.3390/cancers13215309
pmc: PMC8582377
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Kuhbier-Langewiesche foundation and Bavarian Equal Opportunities Sponsorship
ID : none
Références
Thyroid. 2010 Dec;20(12):1341-9
pubmed: 21034228
Endokrynol Pol. 2010 Sep-Oct;61(5):467-73
pubmed: 21049460
J Clin Endocrinol Metab. 2015 Apr;100(4):1529-36
pubmed: 25642591
Eur Thyroid J. 2018 Nov;7(6):313-318
pubmed: 30574462
Endocr J. 2007 Apr;54(2):265-74
pubmed: 17379963
J Clin Endocrinol Metab. 2000 Mar;85(3):1107-13
pubmed: 10720047
Am J Surg Pathol. 2007 Aug;31(8):1256-64
pubmed: 17667551
Thyroid. 2016 Jan;26(1):1-133
pubmed: 26462967
Thyroid. 2019 Mar;29(3):311-321
pubmed: 30747050
J Cancer. 2018 Jan 1;9(2):250-255
pubmed: 29344270
J Nucl Med. 1999 Jun;40(6):986-92
pubmed: 10452315
Clin Endocrinol (Oxf). 2018 Apr;88(4):529-537
pubmed: 29095527
Cancer. 2006 Mar 15;106(6):1286-95
pubmed: 16470605
Eur J Cancer. 2018 Mar;92:40-47
pubmed: 29413688
Cancer Control. 2006 Apr;13(2):119-28
pubmed: 16735986
J Clin Endocrinol Metab. 2014 Apr;99(4):1245-52
pubmed: 24512493
Pathologe. 2019 May;40(3):227-234
pubmed: 31093689
Thyroid. 2021 Mar;31(3):337-386
pubmed: 33728999
World J Surg. 2007 May;31(5):934-45
pubmed: 17431717